Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Canada’s biggest listed drug maker, Valeant Pharmaceuticals International Inc (VRX.TO), is in talks to buy generic drugmaker Actavis Inc (ACT.N) for more than $13 billion, Wall Street Journal reported, citing people familiar with the matter. The companies had been working towards an all-stock deal, when some of Actavis’ directors came out against it around the middle of this week. But executives on the two sides are still working to resurrect the deal, the journal said. Valeant said in February it was in talks to make more acquisitions, and it remains open to discuss a potential “merger of equals.”
Help employers find you! Check out all the jobs and post your resume.
